Avadel Pharmaceuticals Supports the Narcolepsy Network's 5th Annual DREAM BIG Walk
17 5월 2017 - 10:30PM
Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced that on
Sunday, May 14, 2017 the Company supported the Narcolepsy Network’s
5th Annual DREAM BIG Walk in New York City and Seattle. The annual
walks raise funding for the Narcolepsy Network, which helps build
greater disease awareness and provides educational resources and
community support to those effected by narcolepsy.
Executive Director of Narcolepsy Network, Dr.
Eveline Honig, said, “We were very happy to have Avadel’s support
for this year’s walk. Our goal is to continue building awareness
for this misunderstood and under diagnosed sleep disorder. In
addition, it is important that patients and the greater community
stay apprised of ongoing clinical research so that we can continue
to see improvements in narcolepsy treatment.”
Mike Anderson, Avadel’s Chief Executive Officer,
remarked, “Helping to raise disease awareness and promote early
diagnosis are important to Avadel, and we hope that our continued
support of the Narcolepsy Network will help more patients receive
much needed treatment. We are currently enrolling patients in our
REST-ON Phase III trial for once-nightly sodium oxybate, which if
successful, will provide another treatment option for those
suffering from narcolepsy.”
About Avadel’s REST-ON Phase III
Clinical TrialREST-ON is a double-blind, randomized,
placebo controlled study of 264 patients to assess the efficacy and
safety of a once nightly formulation of sodium oxybate for
extended-release oral suspension for the treatment of excessive
daytime sleepiness and cataplexy in patients suffering from
narcolepsy. For more information, please visit
www.rethinknarcolepsy.com.
About Avadel Pharmaceuticals
plc: Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a
specialty pharmaceutical company that seeks to develop
differentiated pharmaceutical products that are safe, effective and
easy to take through formulation development, by utilizing its
proprietary drug delivery technology and in-licensing / acquiring
new products; ultimately, helping patients adhere to their
prescribed medical treatment and see better results. Avadel
currently markets products in the hospital and primary care spaces.
The Company is headquartered in Dublin, Ireland with operations in
St. Louis, Missouri and Lyon, France. For more information, please
visit www.avadel.com.
Safe Harbor: This release may
include "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
herein that are not clearly historical in nature are
forward-looking, and the words "anticipate," "assume," "believe,"
"expect," "estimate," "plan," "will," "may," and the negative of
these and similar expressions generally identify forward-looking
statements. All forward-looking statements involve risks,
uncertainties and contingencies, many of which are beyond Avadel's
control and could cause actual results to differ materially from
the results contemplated in such forward-looking statements. These
risks, uncertainties and contingencies include the risks relating
to: our dependence on a small number of products and customers for
the majority of our revenues; the possibility that our
Bloxiverz®,Vazculep® and Akovaz® products, which are not patent
protected, could face substantial competition resulting in a loss
of market share or forcing us to reduce the prices we charge for
those products; the possibility that we could fail to successfully
complete the research and development for pipeline products we are
evaluating for potential application to the FDA pursuant to our
"unapproved-to-approved" strategy, or that competitors could
complete the development of such product and apply for FDA approval
of such product before us; our dependence on the performance of
third parties in partnerships or strategic alliances for the
commercialization of some of our products; the possibility that our
products may not reach the commercial market or gain market
acceptance; our need to invest substantial sums in research and
development in order to remain competitive; our dependence on
certain single providers for development of several of our drug
delivery platforms and products; our dependence on a limited number
of suppliers to manufacture our products and to deliver certain raw
materials used in our products; the possibility that our
competitors may develop and market technologies or products that
are more effective or safer than ours, or obtain regulatory
approval and market such technologies or products before we do; the
challenges in protecting the intellectual property underlying our
drug delivery platforms and other products; our dependence on key
personnel to execute our business plan; the amount of additional
costs we will incur to comply with U.S. securities laws as a result
of our ceasing to qualify as a foreign private issuer; and the
other risks, uncertainties and contingencies described in the
Company's filings with the U.S. Securities and Exchange Commission,
including our annual report on Form 10-K for the year ended
December 31, 2016, all of which filings are also available on the
Company's website. Avadel undertakes no obligation to update its
forward-looking statements as a result of new information, future
events or otherwise, except as required by law.
Contacts:
Michael F. Kanan
Chief Financial Officer
Phone: (636) 449-1844
E-mail: mkanan@avadel.com
Lauren Stival
Sr. Director, Investor Relations and Corporate Communications
Phone: (636) 449-5866
Email: lstival@avadel.com
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024